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Introduction
Cardiac MRI (CMR) plays an important role in evaluation
of congestive heart failure (CHF). However, despite the
effectiveness of routine clinical CMR in assessment of car-
diac structure and function, CMR does not directly evalu-
ate hemodynamic variables critical to CHF management.
Purpose
We sought to evaluate the role of pulmonary transit time
(PTT) by first pass perfusion CMR in the assessment of
hemodynamic derangement in CHF patients
Methods
Subjects were prospectively enrolled and brain natriuretic
peptide (BNP) and N-terminal proBNP (NT proBNP)
obtained prior to CMR examination. First-pass perfusion
was performed in sagital and coronal planes covering the
main pulmonary artery and left atrium using a saturation
recovery SSFP sequence with 0.005 to 0.01 mmol/kg
gadopentetate. PTT was measured as the time interval
between peak signal intensity in the main pulmonary
artery and peak signal intensity in the left atrium and nor-
malized to heart rate. SSFP cine imaging was performed
for ventricular structure and function evaluation. All par-
ticipants also underwent echocardiography within 2
hours of CMR. Right ventricular (RV) systolic pressure was
estimated using Doppler tricuspid regurgitant velocity.
Tissue Doppler was used to determine the mitral E/e'
ratio.
Results
Of 31 subjects enrolled, 12 were normal controls and 19
CHF patients. Most with CHF (n = 17) were stable outpa-
tients with class I to III NYHA functional class. Compared
to controls, CHF patients had lower LVEF (37% vs 56%, p
< 0.001), and stroke volume (74 ml vs 96 ml, p = 0.005).
There was no significant difference in cardiac output (5.8
L/min vs 5.0 L/min, p = 0.077). However, PTT was signif-
icantly prolonged in CHF patients: 9.0 ± 2.9 s vs 5.7 ± 0.9
s in controls (p < 0.001). Prolonged PTT was closely asso-
ciated with BNP and NT proBNP(r = 0.746 (p < 0.001), r
= 0.789 (p < 0.001), respectively). PTT was also associated
with low LVEF (r = -0.653, p < 0.001), low RVEF (r = -
0.605, p < 0.001), reduced cardiac output (r = -0.533, p =
0.002), RV systolic pressure (r = 0.459, p = 0.032) and
mitral E/e' (r = 0.615, p = 0.002). In multivariate models
including PTT, cardiac output and LVEF, prolonged PTT
was the only predictor of increased BNP (p = 0.003) and
NT proBNP (p = 0.001), suggesting an independent rela-
tionship between PTT and BNP.
Conclusion
PTT was significantly prolonged in CHF patients. Pro-
longed PTT correlated with important biomarkers and
hemodynamic indices of CHF such as increased BNP, NT
proBNP, mitral E/e' and RV systolic pressure. These find-
ings suggest that PTT by CMR is a valuable hemodynamic
marker, likely reflecting total pulmonary resistance
increases due to abnormalities of both the pulmonary vas-
culature and left atrial pressure.
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